Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
12/07/20178:35AMGLOBEXOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.
Expands portfolio of partner-funded programs$240 million in potential milestone paymentsRoyalties ranging from the high single-digits to mid-teens on net salesBeyond XOMA 358, XOMA adds three additional programs to its portfolio for which it is entitled to receive future royalties EMERYVILLE, Calif., Dec. 07, 2017 (GLOBE... More...>>
12/07/20178:30AMGLOBEAntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to...
LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, and XOMA Corporation (“XOMA”) (NASDAQ:XOMA), a pioneer in... More...>>
11/06/20174:05PMGLOBEXOMA Reports Third Quarter 2017 Financial Results
Validated business strategy with transformational license agreements with Novartis;Expanded portfolio of partner-funded programs with potential for future milestone and royalty payments;Current cash balance sufficient to fund operations for approximately five years BERKELEY, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- XOMA... More...>>
10/04/20179:15AMGLOBEXOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries
BERKELEY, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced it has entered into new non-exclusive license agreements with three different companies, Tizona Therapeutics, Inc., Torch Biosciences, Inc... More...>>
09/19/20177:00AMGLOBEXOMA to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present the Company’s strategic initiatives and value drivers at the Cantor Fitzgerald Global... More...>>
09/11/20177:00AMGLOBEXOMA Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics
BERKELEY, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced it has earned a $3 million milestone payment related to the clinical advancement of an anti-botulism product candidate the Company licensed... More...>>
09/06/20177:00AMGLOBEXOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference
BERKELEY, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present the Company’s strategic initiatives and value drivers at the Rodman and Renshaw 19th Annual Global... More...>>
08/25/20177:00AMGLOBEXOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio
$31 million in upfront payments including $5 million equity investment50 percent reduction in XOMA’s outstanding debt through repayment of its €12 million obligation to Les Laboratoires ServierSignificant potential milestone payments plus tiered royalties on sales of gevokizumabMaturity date on XOMA’s debt to Novartis... More...>>
08/09/20174:30PMGLOBEXOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference
BERKELEY, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present the Company’s new strategic initiatives and value drivers at the 2017 Wedbush PacGrow Healthcare... More...>>
08/08/20174:30PMGLOBEXOMA Reports Second Quarter 2017 Financial Results
Executing new corporate strategy leveraging extensive portfolio of partnered programsEarned $10 million milestone payment from a pharmaceutical partnerReduced combined R&D and G&A expenses 56% year-over-yearCurrent cash balance sufficient to fund operations through August 2018 BERKELEY, Calif., Aug. 08, 2017 (GLOBE... More...>>
05/18/20177:00AMGLOBEXOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development
BERKELEY, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced it has earned a $10 million milestone payment, reflecting the clinical advancement of an asset the Company licensed to one of its pharmaceutical partners. ... More...>>
05/15/20174:05PMGLOBEXOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference
BERKELEY, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the Company’s new strategic initiatives and value drivers at the UBS Global Healthcare Conference... More...>>
05/09/20174:05PMGLOBEXOMA Reports First Quarter 2017 Financial Results
Established new corporate strategy leveraging extensive portfolio of partnered programs Strengthened balance sheet with BVF Partners investment and substantial debt repaymentReduced combined R&D and G&A expenses 49% year-over-year BERKELEY, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA... More...>>
04/24/20177:00AMGLOBEXOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition
BERKELEY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that it has achieved positive Phase 2 proof-of-concept results for X213 in physiological hyperprolactinemia (HPRL). X213 is a monoclonal antibody that... More...>>
04/18/20177:00AMGLOBEXOMA Presents Positive Data from PTH1R Monoclonal Antibody Program
BERKELEY, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today the presentation of positive data from pre-clinical studies investigating the activity of its anti-PTH1R antagonist monoclonal antibody (mAb). The antibody... More...>>
03/28/20177:00AMGLOBEXOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research...
BERKELEY, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today the presentation of data from its PTH1R Monoclonal Antibodies Program. The poster, which reports data from a pre-clinical study investigating the efficacy... More...>>
03/23/20177:00AMGLOBEXOMA Announces Four Presentations at the 2017 ENDO Meeting
BERKELEY, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that clinical data for its two hypoglycemia drug candidates, X358 and X129, and a third drug candidate for hypercalcemic endocrine and oncology conditions... More...>>
03/22/20177:00AMGLOBEXOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation
BERKELEY, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it has fully prepaid the outstanding balance of approximately $6.5 million under the Company’s term loan with Hercules Technology Growth Capital, Inc... More...>>
03/16/20177:00AMGLOBEXOMA Reports Fourth Quarter and Full Year 2016 Financial Results
Actions taken in 2016 set the stage for reduced operating costs and capital requirements In early 2017, Company established new strategic direction and value drivers BERKELEY, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies... More...>>
03/14/20177:00AMGLOBEXOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Di...
BERKELEY, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it will issue its fourth quarter and full year 2016 financial results before the market opens on Thursday, March 16, 2017. In conjunction, the Company... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20171212 14:20:30